U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07709520) titled 'Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B' on July 12.
Brief Summary: A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131/GST-HG141 tablets in patients with chronic hepatitis B
Study Start Date: July 10
Study Type: INTERVENTIONAL
Condition:
Chronic Hepatitis B
Intervention:
DRUG: GST-HG141
GST-HG141 is a novel, potent and selective HBV CAM, which has a distinct molecular mechanism of its antiviral action compared to other CAMs reported in the literature, and has demonstrated strong antiviral properties in pre-c...